Loperamide
Spezifikationen
53179-11-6CAS-Nummer
258-416-5EG-Nummer
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamideIUPAC-Name
C29H33ClN2O2Chemische Formel
477 g/molMolekulargewicht
loperamide; 53179-11-6; Loperamida; Loperamidum; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide; Fortasec; DTXSID6045165; 6X9OC3H4II; 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-N,N-dimethyl-2,2-diphenylbutanamide; 4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide; CHEBI:6532; DTXCID4025165; 1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-; NSC696356; RefChem:5959; 258-416-5; Ioperamide; Maalox Anti-Diarrheal; Loperamide (INN); CHEMBL841; Loperamidum [INN-Latin]; Loperamida [INN-Spanish]; NCGC00015608-04; Loperacap; A1CMV; LOPERAMIDE [INN]; Apo-Loperamide; Nu-Loperamide; Rho-Loperamide; Kaopectate II; PMS-Loperamide; Loperamide [INN:BAN]; 1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-.alpha.,.alpha.-diphenyl-; 2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; Imodium A-D Caplets; 4-(p-Chlorophenyl)-4-hydroxy-N,N-dimethyl-.alpha.,.alpha.-diphenyl-1-piperidinebutyramide; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-N,N-dimethyl-2,2-diphenylbutanamide; Diamide (TN); CAS-53179-11-6; EINECS 258-416-5; UNII-6X9OC3H4II; BRN 1558273; Immodium; LoperamideHCl; Spectrum_000374; Tocris-0840; LOPERAMIDE [MI]; LOPERAMIDE [JAN]; Prestwick0_000144; Prestwick1_000144; Prestwick2_000144; Prestwick3_000144; Spectrum2_001738; Spectrum3_001015; Spectrum4_001143; Spectrum5_001374; Lopac-L-4762; LOPERAMIDE [VANDF]; EC 258-416-5; LOPERAMIDE [WHO-DD]; CBiol_001796; Lopac0_000708; Oprea1_109220; SCHEMBL28530; BSPBio_000248; BSPBio_001381; BSPBio_002769; KBioGR_000101; KBioGR_001685; KBioSS_000101; KBioSS_000854; 5-21-02-00379 (Beilstein Handbook Reference); cid_71420; DivK1c_000215; SPBio_001816; SPBio_002187; BPBio1_000274; GTPL7215; HSDB 8344; KBio1_000215; KBio2_000101; KBio2_000854; KBio2_002669; KBio2_003422; KBio2_005237; KBio2_005990; KBio3_000201; KBio3_000202; KBio3_001989; NINDS_000215; Bio1_000082; Bio1_000571; Bio1_001060; Bio2_000101; Bio2_000581; HMS1791F03; HMS1989F03; HMS2089C13; Tox21_110180; BDBM50017698; EBC-27201; EX-A12370; AKOS000573892; Tox21_110180_1; CCG-204793; DB00836; FL65067; SDCCGSBI-0050686.P004; 4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide; IDI1_000215; IDI1_033851; NCGC00015608-01; NCGC00015608-02; NCGC00015608-03; NCGC00015608-05; NCGC00015608-06; NCGC00015608-07; NCGC00015608-08; NCGC00015608-09; NCGC00015608-11; NCGC00015608-13; NCGC00015608-15; NCGC00015608-17; NCGC00015608-24; NCGC00016828-01; NCGC00024818-01; NCGC00024818-02; NCGC00024818-03; NCGC00024818-04; NCGC00024818-05; DA-75076; ST095179; SBI-0050686.P003; CAS-34552-83-5; AB00053697; CS-0892719; NS00002516; C07080; D08144; EN300-708764; AB00053697-12; AB00053697-13; AB00053697_14; AB00053697_15; L000709; Q423751; BRD-K61250553-001-02-9; BRD-K61250553-003-05-8; BRD-K61250553-003-16-5; BRD-K61250553-003-29-8; BRD-K61250553-003-30-6; BRD-K61250553-003-32-2; LOPERAMIDE OXIDE MONOHYDRATE IMPURITY A [EP IMPURITY]; 4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-N,N-dimethyl-2,2-diphenylbutanamide #; 4-[4-(4-chlorophenyl)-4-hydroxypiperidyl]-N,N-dimethyl-2,2-diphenylbutanamide; 4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-N,N-dimethyl-2,2-diphenyl-butyramide(loperamide)Synonyme
